Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Alight Q3 net loss narrows 95% to $51 million; Q3 revenue falls 6% to $500 million

Alight Q3 net loss narrows 95% to $51 million; Q3 revenue falls 6% to $500 million

BitgetBitget2026/11/03 21:21
  • Alight’s third-quarter 2026 net loss narrowed 95% year over year to $51 million.
  • Revenue fell 6% to $500 million, primarily due to lower net commercial activity.
  • Cash from operations for the nine months ended September 30, 2026, dropped 23% year over year to $181 million.
  • The quarter also included the acquisition of Abett, while CEO Rohit Verma reported significantly improved retention metrics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alight Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202611031605BIZWIRE_USPR_____20261103_BW656676) on November 03, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41
"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss

Novo Nordisk reports that some patients treated with Wegovy have shown improvements in liver conditions.

智通财经•2026/11/09 06:41
Wegovy improves multiple liver indicators in non-obese liver disease patients, and Novo Nordisk (NVO.US) is expected to expand its market beyond weight loss